Certainly. That is of course something that has been identified in almost every report that has come out about the translation of discoveries into actual utility or application. Right now, we're trying to work with these industries and other end users. Sometimes there are regulatory issues and policy issues, or it may be something within industry, a gap that needs to be filled to address this.
We plan to work with those industries up front when we're developing our competitions, in order to get our scientists to work with them up front to ensure that there's actually uptake at the other end. This is sometimes part of the problem.
For example, a project that we're funding now is working on swine health. The actual pig breeders came together as a coalition in Canada and submitted a research project with a group of academic scientists. They're working together in a project and they know that the scientists will be delivering to them results and data that they can then use in their industry. That's a very important part.
We're also learning that we need to work with pharmaceutical companies in a new way, in more of a public-private partnership way, because they are struggling right now. For a lot of them, their patents are going off, and soon they will not be making the money they've made in the past. Drug discovery has been low.